Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06254690
Status:
RECRUITING
Last Update Posted:
2024-02-12
First Post:
2024-01-28
Brief Title:
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer a Phase II Clinical Study
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01-01
Start Date Type:
ACTUAL
Primary Completion Date:
2026-11-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-01-28
First Submit QC Date:
February 4 2024
Study First Post Date:
2024-02-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-04
Last Update Post Date:
2024-02-12
Last Update Post Date Type:
ACTUAL